Molecular Templates Inc
NASDAQ:MTEM
Intrinsic Value
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. [ Read More ]
The intrinsic value of one MTEM stock under the Base Case scenario is 3.52 USD. Compared to the current market price of 1.47 USD, Molecular Templates Inc is Undervalued by 58%.
Valuation Backtest
Molecular Templates Inc
Run backtest to discover the historical profit from buying and selling MTEM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Molecular Templates Inc
Current Assets | 16.8m |
Cash & Short-Term Investments | 11.5m |
Receivables | 250k |
Other Current Assets | 5m |
Non-Current Assets | 18.6m |
PP&E | 16.6m |
Other Non-Current Assets | 2.1m |
Current Liabilities | 17.3m |
Accounts Payable | 1.5m |
Accrued Liabilities | 6.8m |
Other Current Liabilities | 9m |
Non-Current Liabilities | 13.9m |
Other Non-Current Liabilities | 13.9m |
Earnings Waterfall
Molecular Templates Inc
Revenue
|
57.3m
USD
|
Operating Expenses
|
-67.8m
USD
|
Operating Income
|
-10.5m
USD
|
Other Expenses
|
2.3m
USD
|
Net Income
|
-8.1m
USD
|
Free Cash Flow Analysis
Molecular Templates Inc
What is Free Cash Flow?
MTEM Profitability Score
Profitability Due Diligence
Molecular Templates Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Molecular Templates Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
MTEM Solvency Score
Solvency Due Diligence
Molecular Templates Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Molecular Templates Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MTEM Price Targets Summary
Molecular Templates Inc
According to Wall Street analysts, the average 1-year price target for MTEM is 16.5 USD .
Ownership
MTEM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MTEM Price
Molecular Templates Inc
Average Annual Return | -13.41% |
Standard Deviation of Annual Returns | 95.61% |
Max Drawdown | -99% |
Market Capitalization | 9.7m USD |
Shares Outstanding | 6 583 880 |
Percentage of Shares Shorted | 0.88% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 261 full-time employees. The company went IPO on 2005-02-04. The firm utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The firm is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.
Contact
IPO
Employees
Officers
The intrinsic value of one MTEM stock under the Base Case scenario is 3.52 USD.
Compared to the current market price of 1.47 USD, Molecular Templates Inc is Undervalued by 58%.